Chemotherapy induced nausea and vomiting: A European perspective

British Journal of Nursing

Volumn 20, Issue 10 SUPPL., 2011, Pages

  Vidall, Cheryl ^a  

^a Healthcare at Home Ltd   (United Kingdom)

Author keywords

CINV; International guidelines; Optimal symptom control; Patient risk assessment; Protocols

Indexed keywords

EID: 79957754190     PISSN: 09660461     EISSN: None     Source Type: Journal    
DOI: 10.12968/bjon.2011.20.sup5.s22     Document Type: Article

References (14)

1. American Society of Clinical Oncology (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 24(18) 2932-47
2. Common Terminology Criteria for Adverse Events (CTCAE) Version v4.03 (June 14, 2010) U.S. Department of Health and Human Services. National Institutes of Health, National Cancer Institute
3. Geling O, Eichler HG (2005) Should 5-Hydroxytryptamine-3 receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications. J Clin Oncol 23(6): 1289-94 (Pubitemid 46202287)
4. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17: 2971-94 (Pubitemid 29415258)
5. Gregory RE, Ettinger DS (1998) 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 55: 173-89 (Pubitemid 28081623)
6. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329: 1790-6 (Pubitemid 23355554)
7. Grunberg SM, Hansen M, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100: 2261-8 (Pubitemid 38580348)
8. Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15: 103-9 (Pubitemid 27020563)
9. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4: 191-6 (Pubitemid 29297482)
10. Lindley C (1999) Perception of chemotherapy side effects: cancer vs noncancer patients. Cancer Practice 7: 59-65 (Pubitemid 29148608)
11. Multinational Association of Supportive Care in Cancer (2009) Antiemetic prophylaxis and therapy- MASCC/ESMO Consensus Conference on Antiemetic Therapy. www.mascc.org
12. National Comprehensive Cancer Network V.1.2010 Antiemesis Clinical Practice Guidelines www.nccn.org
13. O'Kane A, Rankin M, Munro G, Wilkie U, Donnan P, Parsons M (2009) Reduction in nausea and vomiting through adherence to MASCC (Multinational Association of Supportive Care in Cancer) Antiemetic Guideline for platinum chemotherapy. MASCC, Rome.
14. Rojas C, Thomas A, Alt J et al (2009) Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626(2-3): 193-9